Back to news

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

Globe Newswire•18/11/2026•18:01 ET
1

Key Highlights

  • ➤MICVO confirmed ORR reached 39% among 33 efficacy-evaluable patients
  • ➤MICVO median duration of response reached 9.2 months
  • ➤MICVO median PFS reached 6.7 months versus 4.2 months on most recent prior therapy
  • ➤Six Grade 3 peripheral neuropathy cases improved; five resolved to Grade 1 or better
  • ➤Global Phase 3 Headliner trial planned to initiate in mid-2027

Expert Statements

Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology

“We are grateful to the EORTC-NCI-AACR Symposium for highlighting these updated MICVO data in 2L+ R/M HNSCC, and to Dr. Johnson for presenting these important new results. The data from October show improvements across multiple key clinical activity endpoints with a novel analysis showing that MICVO increased mPFS by 50% versus the most recent prior therapy patients had received before MICVO. We are also very happy to report that our clinical strategy for managing safety has had the intended impact. There have been no new cases of Grade 3 peripheral neuropathy and the six patients that experienced Grade 3 peripheral neuropathy have all improved with five of the six patients resolving to Grade 1 or better. Collectively, this updated data profile, and the new analyses further support our plan to advance MICVO into the global Phase 3 Headliner(SM) trial in 2L+ R/M HNSCC, which we expect to initiate in mid-2027. With important regulatory meetings in the near term and more mature overall survival (OS) data expected in the first half of 2027, we remain confident in our path forward.”

Faye Johnson, Professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center

“For patients whose disease progresses after platinum chemotherapy and immunotherapy, there remains a substantial unmet medical need, particularly as we anticipate broader use of EGFR-targeted therapies in earlier lines of treatment. It is reassuring to see responses that last in this setting and, if confirmed in a larger study, MICVO could potentially offer these patients a meaningful new treatment option.”

Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months

Clinical activity consistent across HPV status and prior-treatment subgroups, with a manageable safety profile

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in